Please login to the form below

Not currently logged in
Email:
Password:

Targacept

This page shows the latest Targacept news and features for those working in and with pharma, biotech and healthcare.

Novartis launches Alzheimer’s prevention study

Novartis launches Alzheimer’s prevention study

This has been influenced by several major late-stage trial failures for drugs that were intended for late-stage use, including yesterday's announcement that Targacept had dropped development of

Latest news

  • Another Alzheimer’s failure as Targacept trial disappoints Another Alzheimer’s failure as Targacept trial disappoints

    Another Alzheimer’ s failure as Targacept trial disappoints. Targacept drops development of drug after disappointing study results. ... As a result Dr Stephen Hill confirmed that Targacept “ do[es] not intend to invest in further development of

  • FDA to review safety of AZ's saxagliptin FDA to review safety of AZ's saxagliptin

    Reduces Targacept alliance. Meanwhile, AZ will return rights to several preclinical compounds licensed from US biopharma company Targacept, amending a collaboration that has been ongoing between the two companies since 2005. ... The identity of the

  • Setback for Roche as schizophrenia candidate fails studies Setback for Roche as schizophrenia candidate fails studies

    Meanwhile, pharma companies have struggled to bring novel antipsychotics to market, with Lilly dropping pomaglumetad methionil in 2012 and Targacept giving up on TC-5619 towards the end of last year.

  • AZ pays $273m for Ardelyx renal disease drug AZ pays $273m for Ardelyx renal disease drug

    The company needs to bolster its pipeline in the wake of a series of late-stage failures, including Targacept-partneredand motavizumab for respiratory syncytial virus (RSV), and the loss of patent

  • Targacept to cut more jobs after ADHD trial failure Targacept to cut more jobs after ADHD trial failure

    Targacept to cut more jobs after ADHD trial failure. TC-5619 disappoints in phase II trial after missing primary endpoint. ... According to Targacept, patients in the placebo dose group consistently improved more than patients taking the actual medicine.

More from news
Approximately 2 fully matching, plus 16 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
EY Life Sciences

Our global reach Against a backdrop of regulatory, digital, financial and global transformation, Life Sciences companies are finding integration and...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics